title: The configuration of biomolecular markers in cancer of the uterine cervix. Personalized therapy. Monitoring and prognosis.
abstract: BACKGROUND
  The paper deals with the diagnosis of some aggressive forms of uterine cervix cancers, resistant to radio chemotherapy, using biomolecular markers.For this study, the destruction of tumours in stages II-IIIBis carried out by hyperthermia induced by different sources of energy. The aimed targets are toembed a quick and simple technique of haemostas isused in bleeding uterine cervix tumours associated with acute an aemiain the treatment protocols and to identify biomolecular criteria revealing tumour aggressiveness and treatment response.
  
  
  METHODS
  The proposed method consists in radio frequency ablation (RFA) applied touterine cervix bleeding tumours with acute secondary anaemia. Studying 16 patients displaying aggressive cancer forms resistant to radio chemotherapy treated by the above mentioned method, we assessed that the commonly present markers: Ki67, p53 and Bcl-2, may be a substantial indication of such cases. Aggressiveness and treatment resistance was defined based on clinical and paraclinical investigations.
  
  
  RESULTS
  RFA haemostasis achieved in approximately 20 m inproved the efficiency of this method. A secondary important effect was local tumour volume decrease, resulting in the improvement of radio-chemotherapy responsiveness.
  
  
  CONCLUSIONS
  Once an aggressive and radio-chemotherapy resistant cancer is diagnosed,the quantitative, qualitative and associative presence of the biomolecular markers mentioned herein before, could influence the personalised treatment attitude (radiofrequency, neoadjuvant chemotherapy), which onthe long term, may increase patient survival and life quality improvement.
authors.forename: V M
authors.initials: VM
authors.lastname: Prunoiu
authors.forename: M A
authors.initials: MA
authors.lastname: Marincaş
authors.forename: C
authors.initials: C
authors.lastname: Cirimbei
authors.forename: S
authors.initials: S
authors.lastname: Ionescu
authors.forename: S
authors.initials: S
authors.lastname: Zurac
authors.forename: M
authors.initials: M
authors.lastname: Radu
authors.forename: R
authors.initials: R
authors.lastname: Nicolaescu
authors.forename: E
authors.initials: E
authors.lastname: Brătucu
authors.forename: N D
authors.initials: ND
authors.lastname: Straja
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000601:surgery; D017115:Catheter Ablation / Q000379:methods; D005260:Female; D019254:Genes, bcl-2; D006801:Humans; D019394:Ki-67 Antigen / Q000097:blood*; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011788:Quality of Life; D012680:Sensitivity and Specificity; D016896:Treatment Outcome; D016159:Tumor Suppressor Protein p53 / Q000097:blood*; D002583:Uterine Cervical Neoplasms / Q000097:blood / Q000175:diagnosis* / Q000235:genetics / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53